Geron Corporation’s Exciting Prospects Amidst Imetelstat’s Regulatory Review

Photo of author
Written By Jackson Hartwell

Geron Corporation (NASDAQ: GERN), a biopharmaceutical company, recently experienced a notable stock rally driven by favorable developments in its regulatory journey, particularly concerning its promising drug candidate, imetelstat.

This treatment, targeting lower-risk myelodysplastic syndromes (LR-MDS), has reached a critical phase with its upcoming Prescription Drug User Fee Act (PDUFA) target date on June 16, 2024, presenting a crucial event for the company and its investors.

Optimistic FDA Advisory Committee Outcome

The optimism surrounding Geron’s prospects was significantly bolstered in March when the FDA’s advisory committee voted 12-2 in favor of imetelstat’s clinical benefit/risk profile.

Credit: DepositPhotos

This vote is a pivotal endorsement as it often serves as a key influencer in the FDA’s final approval decisions. The positive outcome led to a surge in Geron’s stock, highlighting the market’s response to potential regulatory successes.

Ongoing Clinical Trials and Developmental Insights

Geron is not only focused on imetelstat’s application in LR-MDS but is also exploring its efficacy in treating myelofibrosis through two significant trials: IMpactMF and IMproveMF.

The IMproveMF trial, which examines the combination of imetelstat with ruxolitinib in higher-risk cases of myelofibrosis, is particularly noteworthy.

Despite not having a definitive timeline for preliminary results, the progression to higher dosing levels indicates steady advancement.

An interim analysis from the IMpactMF trial is expected in the first half of 2025, with a final analysis due in 2026, underscoring the long-term potential of the drug beyond the current focus on LR-MDS.

Financial Health and Funding Strategy

As of the end of 2023, Geron reported having a strong financial base with $378.1 million in cash, cash equivalents, and marketable securities.

The company’s financial strategy was further strengthened by a recent equity offering expected to net approximately $140 million.

This capital raise should extend Geron’s operational runway well into Q3 2025, even with anticipated increases in operating expenses as the company ramps up for potential commercialization and continued investment in its clinical trials.

Comparative Market Analysis

It is instructive to compare Geron’s market dynamics and user engagement metrics against those of its peers in the biopharmaceutical sector.

While Geron does not face the same type of user engagement metrics as tech platforms, its engagement with investors and stakeholders through clinical trial updates and regulatory interactions is pivotal.

The company’s ability to maintain transparency and deliver on its developmental milestones is crucial for sustaining investor confidence and supporting its stock price.

Risks and Forward-Looking Considerations

  • Regulatory Risk: Any delays or negative outcomes related to imetelstat’s approval could adversely affect the stock.
Credit: DepositPhotos
  • Clinical Trial Risks: Unfavorable results from ongoing trials could impact the perceived efficacy and safety of imetelstat.


  • Financial Management Risks: Effective allocation and management of the newly raised funds are critical, especially as the company navigates through increased operational expenses.

A Cautious Hold with Potential for Future Growth

While the FDA advisory committee’s favorable vote for imetelstat has significantly de-risked the investment in Geron, the remaining regulatory pathway still presents potential challenges.

Therefore, investors are advised to stay tuned for the FDA’s decision in June, which will likely be a significant catalyst for Geron’s stock eit


You should read and understand this disclaimer in its entirety before joining or viewing the website or email/blog list of (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help.

The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at; the Financial Industry Regulatory Authority (the "FINRA") at, and relevant State Securities Administrator website and the OTC Markets website at The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.

The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.

By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link: and

By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.